Aktiesnakken — December 2010
-
novozymes insidersalg
-
man kan spørge sig selv hvad der har ændret sig selv for Credit Suisse, efter de totalt underminerede Arzerra
-
-
godmorgen
-
Godmorgen
-
vi er jo nogen der husker deres analyse under krisen hvor de sagde at arzerra aldrig ville flyve nogle steder. mener de var helt nede på 8
-
mill i arzerra salg for 2010
-
hvis de spår Genmab til et milliard overskud (1,5 mia DKK - 500 mill costs) så kan neutraliteten da kun gå på at de tager 5 år
-
idag ser vi gerne fortsættelsen på colo, lcp, h+h
-
og så den stoooore kamp i aften!
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind